Blueberry derived exosome like nanoparticles alleviate CCl4 induced acute liver injury by inhibiting ACSL4−ALOX15 mediated ferroptosis
Ruolan Liu , Feng Zhang , Chuanhai Zhang , Tongxiao Xu , Teng Wang , Yanan Wang , Ying Ding , Kunlun Huang , Xiaoyun He
Food Innovation and Advances ›› 2026, Vol. 5 ›› Issue (2) : 287−302
Blueberry (Vaccinium spp.), a flowering plant in the family Ericaceae, is rich in bioactive compounds such as polyphenols, anthocyanins, and flavonoids, which exhibit anti-inflammatory, antioxidant, and anticancer properties. Increasing evidence suggests that plant-derived exosome-like nanoparticles (PELNs) possess diverse therapeutic activities and hold promise for improving liver function. Acute liver injury (ALI) is a clinical syndrome for which effective pharmacological interventions remain limited. The present study aimed to investigate whether orally administered blueberry-derived exosome-like nanoparticles (BELNs) can ameliorate ALI and to elucidate the underlying mechanisms. Both in vivo and in vitro experiments demonstrated that BELNs significantly attenuated CCl4-induced ALI. Specifically, BELNs reduced oxidative stress and inhibited the accumulation of lipid peroxidation products. Mechanistic analyses revealed that BELNs alleviated lipid peroxidation and ferroptosis by suppressing the ACSL4–ALOX15 signaling pathway, specifically reducing its expression by approximately 70% (p <0.001) and thereby protecting hepatocytes from injury. Further investigation identified procyanidin B2 (PCB2) as one of the key active components in BELNs responsible for their antioxidant effects. In summary, this study provides new insights into the therapeutic potential of blueberries and their derived natural products and establishes a mechanistic basis for the clinical translation of PELNs.
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
/
| 〈 |
|
〉 |